首页>
外国专利>
Methods of Subtyping CRC and their Association with Treatment of Colon Cancer Patients with Oxaliplatin
Methods of Subtyping CRC and their Association with Treatment of Colon Cancer Patients with Oxaliplatin
展开▼
机译:奥沙利铂治疗大肠癌的分型方法及其与结肠癌的关系
展开▼
页面导航
摘要
著录项
相似文献
摘要
A gene expression signature identifies stage II colon cancer patients who will receive benefit from oxaliplatin. Oxaliplatin has been shown to lengthen the survival of colon cancer patients, when it is combined with 5-fluorouracil plus leucovorin (FULV) in NSABP clinical trial C-07. Gene expression signatures are used first to classify tumors with regard to their respective subtypes, enterocyte, TA, goblet, inflammatory and stem-like and detection of expression of the enterocyte subtype directs treatment of the patient with oxaliplatin.
展开▼